AZD3427, a relaxin mimetic in pulmonary hypertension group 2 associated with left heart disease: design and rationale of the phase 2b Re-PHIRE Study

被引：0
|
作者：
Ufnal, M. [1 ]
Connolly, K. [2 ]
Guazzi, M. [3 ]
Bonderman, D. [4 ]
Ezekowitz, J. [5 ]
Gustafsson, F. [6 ]
Ciurzynski, M. [7 ]
Vilella, R. Lopez [8 ]
Tariq, A. [9 ]
Gardner, R. [10 ]
Jansa, P. [11 ,12 ]
Van Wijk, S. [13 ]
Kinugawa, K. [14 ]
Bjorklund, E. [15 ]
Rosenkranz, S. [16 ]
机构：
[1] BioPharmaceut R&D, Early Clin Dev Cardiovasc Renal & Metab, AstraZeneca, Warsaw, Poland
[2] BioPharmaceut R&D, Early Clin Dev Cardiovasc Renal & Metab, AstraZeneca, Cambridge, England
[3] Univ Milan, San Paolo Hosp, Sch Med, Milan, Italy
[4] Med Univ Vienna, Div Cardiol, Dept Internal Med 2, Vienna, Austria
[5] Univ Alberta, Canadian VIGOUR Ctr, Edmonton, AB, Canada
[6] Univ Copenhagen Hosp, Ctr Heart, Copenhagen, Denmark
[7] Med Univ Warsaw, Dept Internal Med & Cardiol, Warsaw, Poland
[8] La Fe Univ & Polytech Hosp, Heart Failure & Transplantat Unit, Valencia, Spain
[9] Yale Sch Med, Heart Failure Program, New Haven, CT USA
[10] Golden Jubilee Natl Hosp, Scottish Natl Adv Heart Failure Serv, Clydebank, Scotland
[11] Charles Univ Prague, Prague, Czech Republic
[12] Gen Univ Hosp, Dept Med 2, Prague, Czech Republic
[13] Zuyderland Med Ctr, Dept Cardiol, Heerlen, Netherlands
[14] Univ Hosp, Dept Internal Med 2, Toyama, Japan
[15] Uppsala Univ Hosp, Dept Med Sci, Uppsala, Sweden
[16] Cologne Cardiovascu Iar Res Ctr CCRC, Dept Cardiol Pulmonol & Intens Care Med, Ctr Mol Med Cologne CMMC, Cologne, Germany
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2024年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：216 / 216
页数：1
相关论文
共 11 条
  • [1] Relaxin mimetic in pulmonary hypertension associated with left heart disease: Design and rationale of Re-PHIRE
    Ufnal, Marcin
    Connolly, Kathleen
    Millegard, Marcus
    Surkova, Elena
    Guazzi, Marco
    Bonderman, Diana
    Ezekowitz, Justin
    Gustafsson, Finn
    Ciurzynski, Michal
    Vilella, Raquel Lopez
    Ahmad, Tariq
    Gardner, Roy
    Jansa, Pavel
    van Wijk, Sandra
    Kinugawa, Koichiro
    Bjorklund, Erik
    Jing, Zhi-Cheng
    Rosenkranz, Stephan
    ESC HEART FAILURE, 2025,
  • [2] Pulmonary hypertension associated with left heart disease (group 2)
    Wissmueller, Max
    Tichelbaecker, Tobias
    Finke, Karl
    Dohr, Johannes
    Adler, Joana
    Ochs, Laurin
    Hohmann, Christopher
    Baldus, Stephan
    Rosenkranz, Stephan
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (23) : 1498 - 1506
  • [3] Pulmonary hypertension associated with left heart disease (group 2)
    Schmidt, Kai Helge
    Bikou, Olympia
    Blindt, Ruediger
    Bruch, Leonhard
    Felgendreher, Ralf
    Hohenforst-Schmidt, Wolfgang
    Holt, Stephan
    Ladage, Dennis
    Pfeuffer-Jovic, Elena
    Rieth, Andreas
    Schmeisser, Alexander
    Schnitzler, Katharina
    Stadler, Stefan
    Steringer-Mascherbauer, Regina
    Yogeswaran, Athiththan
    Kuebler, Wolfgang M.
    PNEUMOLOGIE, 2023, 77 (11): : 926 - 936
  • [4] INHALED IMATINIB FOR PULMONARY ARTERIAL HYPERTENSION CLINICAL TRIAL: DESIGN OF THE IMPACT PHASE 2B/3 STUDY DESIGN
    Gillies, Hunter
    Chakinala, Murali M.
    Dake, Ben
    Feldman, Jeremy P.
    Hoeper, Marius M.
    Humbert, Marc
    Jing, Zhi-Cheng
    Langley, Jonathan
    McLaughlin, Vallerie
    Niven, Ralph
    Rosenkranz, Stephan H.
    Zhang, Xiaosha
    Hill, Nicholas S.
    CHEST, 2022, 162 (04) : 2325A - 2329A
  • [5] Lung Capillary Stress Failure and Arteriolar Remodelling in Pulmonary Hypertension Associated with Left Heart Disease (Group 2 PH)
    Dayeh, Nour R.
    Ledoux, Jonathan
    Dupuis, Jocelyn
    PROGRESS IN CARDIOVASCULAR DISEASES, 2016, 59 (01) : 11 - 21
  • [6] A Pharmacokinetic/Pharmacodynamic Based Rationale for Dose Selection of the TPH Inhibitor Rodatristat Ethyl in ELEVATE-2-a Phase 2b Study in Pulmonary Arterial Hypertension
    Johnson, B.
    Palacios, M.
    Zhou, J.
    Schmith, V. D.
    Wring, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [7] Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study
    Nathan, Steven D.
    Behr, Juergen
    Collard, Harold R.
    Cottin, Vincent
    Hoeper, Marius M.
    Martinez, Fernando J.
    Corte, Tamera J.
    Keogh, Anne M.
    Leuchte, Hanno
    Mogulkoc, Nesrin
    Ulrich, Silvia
    Wuyts, Wim A.
    Yao, Zhen
    Boateng, Francis
    Wells, Athol U.
    LANCET RESPIRATORY MEDICINE, 2019, 7 (09): : 780 - 790
  • [8] Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia
    Heerspink, Hiddo J. L.
    Stack, Austin G.
    Terkeltaub, Robert
    Greene, Tom A.
    Inker, Lesley A.
    Bjursell, Magnus
    Perl, Shira
    Rikte, Tord
    Erlandsson, Fredrik
    Perkovic, Vlado
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 (08) : 1461 - 1471
  • [9] uniPHied: A Novel Platform Study Design for a Phase 2 Clinical Trial to Assess the Safety and Efficacy of AER-901 in Pulmonary Hypertension Associated With Interstitial Lung Disease and Pulmonary Arterial Hypertension
    Mclaughlin, V. V.
    Ghofrani, H. A.
    Shlobin, O. A.
    Rajagopal, S.
    Hoeper, M.
    Molyneaux, P. L.
    Burgess, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [10] Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction
    Voors, Adriaan A.
    Shah, Sanjiv J.
    Bax, Jeroen J.
    Butler, Javed
    Gheorghiade, Mihai
    Hernandez, Adrian F.
    Kitzman, Dalane W.
    McMurray, John J. V.
    Wirtz, Antonieta Bomfim
    Lanius, Vivian
    van der Laan, Michael
    Solomon, Scott D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 (11) : 1601 - 1610
12